Analyst Upgrades: ARIA, CYTK, and GRUB

Analysts issued bullish notes on Ariad Pharmaceuticals, Inc. (ARIA), Cytokinetics, Inc. (CYTK), and GrubHub Inc (GRUB)

by Elizabeth Harrow

Published on Dec 31, 2014 at 9:25 AM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are upwardly revising their ratings today on oncology specialist Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), biopharmaceutical firm Cytokinetics, Inc. (NASDAQ:CYTK), and mobile carry-out platform GrubHub Inc (NYSE:GRUB). Here's a quick look at today's bullish brokerage notes on ARIA, CYTK, and GRUB.

  • Late Tuesday, JMP Securities raised its price target on ARIA to $8 from $7, and reiterated its "outperform" rating. The new target implies expected upside of 17.3% from yesterday's close at $6.82 -- which, for the record, means Ariad Pharmaceuticals, Inc. finished Tuesday completely flat for 2014. Despite the stock's lack of progress this calendar year -- and a recent downgrade from Credit Suisse -- most analysts remain in ARIA's corner. The stock sports 60% "strong buy" ratings from brokerage firms, with not a single "sell" to be found.

  • CYTK has jumped more than 7% in pre-market trading, aided by a price-target hike to $18 from $13 at Roth Capital. The brokerage firm apparently expects Cytokinetics, Inc. shares to gain nearly 161% from Tuesday's close at $6.90, though the stock has added just 6.2% over the last 12 months. In fact, CYTK only made its way into positive year-to-date territory on Monday, as traders cheered reports of an investment from Japanese firm Astellas Pharma. During the short term, a rush to cover by some of the weaker bearish hands could help CYTK extend its recent rally. The stock's short-interest ratio stands at 5.3, indicating more than a week's worth of pent-up buying pressure, at CTYK's average daily trading volume.

  • After yesterday's close, Barrington Research upgraded GRUB to "outperform" from "market perform," with a $43 price target -- roughly 20% north of the stock's Tuesday finish at $35.87. GrubHub Inc is up more than 3% ahead of the bell, which should help the shares extend a slim lead over resistance at their 80-day moving average (currently located at $35.72). While GRUB has floundered in recent months, and is now trading below its April 4 debut price of $40, the stock still has plenty of support from the brokerage community. Eight out of 10 analysts call GRUB a "buy" or better, and the average 12-month price target of $45.44 is less than 1 point south of the stock's Aug. 13 all-time high at $45.80.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
Puts Popular as GM Stock Rallies
GM puts are all the rage lately
JetBlue Stock Surging Despite Sector Skepticism
J.P. Morgan Securities downgraded JBLU to "neutral" from "overweight"
The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.